Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?

Research output: Contribution to journalEditorialOtherpeer-review

Original languageEnglish
Pages (from-to)169-170
Number of pages2
JournalBritish Journal of Haematology
Volume177
Issue number2
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • inhibitor
  • T-cell acute lymphoblastic leukaemia
  • TYK2

Cite this

@article{a95405531c8a4c70abff6dc26fac4d18,
title = "Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?",
keywords = "inhibitor, T-cell acute lymphoblastic leukaemia, TYK2",
author = "Curtis, {David J.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/bjh.14559",
language = "English",
volume = "177",
pages = "169--170",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons",
number = "2",

}

Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL) : what makes T-ALL TYK? / Curtis, David J.

In: British Journal of Haematology, Vol. 177, No. 2, 01.04.2017, p. 169-170.

Research output: Contribution to journalEditorialOtherpeer-review

TY - JOUR

T1 - Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL)

T2 - what makes T-ALL TYK?

AU - Curtis, David J.

PY - 2017/4/1

Y1 - 2017/4/1

KW - inhibitor

KW - T-cell acute lymphoblastic leukaemia

KW - TYK2

UR - http://www.scopus.com/inward/record.url?scp=85013480732&partnerID=8YFLogxK

U2 - 10.1111/bjh.14559

DO - 10.1111/bjh.14559

M3 - Editorial

VL - 177

SP - 169

EP - 170

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -